Announcement:
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma